Evidence map›Paper›PMID 36479255›Full record

ArticleMolecular and clinical oncology2022

Attitudes towards COVID‑19 vaccination in patients with cancer: A cross‑sectional study of 12 oncology centers.

Raluca Lazar, Cristina Marinela Oprean, Larisa Maria Badau, Geanina Miron, Loredana Draganescu, Tunde Torok-Vistai, Iulia Coroian, Diana Sabau, Alexandru Iliescu, Loredana Aracs Tamas and 9 more

Open access · diamondAbstract read
In one paragraph

Article in Molecular and clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Vaccination status and attitudes towards COVID-19 vaccination in patients undergoing active cancer treatment in a referral center in Mexico: a survey study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 1 country.

Raluca LazarOncology Department, 'Prof. Dr. Ion Chiricuta' Oncology Institute, 400015 Cluj-Napoca, Romania.
Cristina Marinela OpreanANAPATMOL Research Center, 'Victor Babes' University of Medicine and Pharmacy, 300041 Timisoara, Romania.
Larisa Maria BadauDepartment of Oncology, ONCOHELP Hospital Timisoara, 300239 Timisoara, Romania.
Geanina MironDepartment of Oncology, Emergency County Hospital, 420094 Bistrita, Romania.
Loredana DraganescuDepartment of Oncology, Emergency County Hospital, 420094 Bistrita, Romania.
Tunde Torok-VistaiHematology Department, 'Prof. Dr. Ion Chiricuta' Oncology Institute, 400015 Cluj-Napoca, Romania.
Iulia CoroianOncology Department, Baia Mare Emergency County Hospital, 43003 Baia Mare, Romania.
Diana SabauOncology Department, Pelican Hospital Oradea, 410469 Oradea, Romania.
Alexandru IliescuOncology Department, Zalau Emergency County Hospital, 450129 Zalău, Romania.
Loredana Aracs TamasOncology Department, Satu-Mare Emergency County Hospital, 440011 Satu-Mare, Romania.
Sorin HosuOncology Department, Alba-Iulia Emergency County Hospital, 510073 Alba-Iulia, Romania.
Razvan CurcaOncology Department, Alba-Iulia Emergency County Hospital, 510073 Alba-Iulia, Romania.
Alexandra GatejOncology Department, Amethyst Oncology Clinic Timisoara, 307160 Dumbravita Timis, Romania.
Amalia HoraOncology Department, Emergency Hospital, Oradea, 410169 Oradea, Romania.
Andrei UngureanuOncology Department, Amethyst Oncology Clinic Cluj, 407280 Floresti Cluj, Romania.
Doru ParvuOncology Department, CardioMed, 400015 Cluj-Napoca, Romania.
Dan ValeanOncology Department, 'Prof. Dr. Octavian Fodor' Regional Institute of Gastroenterology and Hepatology, 400162 Cluj-Napoca, Romania.
Lia Oxana UsatiucOncology Department, 'Iuliu Hateganu' University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
Radu VidraOncology Department, 'Prof. Dr. Octavian Fodor' Regional Institute of Gastroenterology and Hepatology, 400162 Cluj-Napoca, Romania.
Institute of Oncology Prof. Dr. Ion Chiricuta · ROInstitutul Regional de Gastroenterologie Prof. Dr. Octavian Fodor · ROUniversity of Oradea · ROIuliu Hațieganu University of Medicine and Pharmacy · ROResearch Institute for Analytical Instrumentation · ROVictor Babeș University of Medicine and Pharmacy Timișoara · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with cancer are a high-priority population for COVID-19 vaccination, as per guideline recommendations. The present cross-sectional study was performed to assess the perception of patients with cancer from Romania regarding COVID-19 vaccines. The study included 932 patients with solid and hematologic malignancies. This was a multicenter study including 12 oncology centers located in Western and Northwestern Romania. Between December 2021 and January 2022, patients with cancer completed an individual paper questionnaire regarding acceptance of the SARS-CoV-2 vaccination, type of vaccine, side effects and source of information. During the first year of the vaccination campaign in Romania, 58.05% (541/932) of the investigated patients received COVID-19 vaccines. The vaccination rate was highest in the 61-70 year age group (61.22%). The most frequently used vaccine was Pfizer-BioNTech (72%). There was a statistically significant association between the rate of vaccination and the area of residence and level of education (P<0.001), with rural residence and a lower level of education being predictive factors for COVID-19 vaccination hesitancy. Patients living in rural areas used non-medical sources (e.g. mass media, social platforms) as their main source of information (53.40%, 204/382), whereas patients living in urban areas (64.90%, 357/550) used predominantly medical sources (e.g. recommendations from oncologists and general practitioners). The main source of information among non-vaccinated patients was mass media (e.g. television, radio); 72.38% vs. 29.67% among vaccinated patients. For the latter, the primary source of information was the recommendations made by oncologists (59.70%) and general practitioners (56.76%). The most commonly reported side effect was injection site pain (20-33% for the first dose and 5-27% for the second dose). In conclusion, the present study confirmed that patients with cancer may be reluctant to receive a COVID-19 vaccine, mainly due to the fear of its potential side effects. Although there is scientific evidence to support the efficacy and safety of vaccines, the primary source of information for patients may affect vaccine uptake, thus affecting the efforts to stop the pandemic. Furthermore, the present study revealed that non-vaccinated patients preferred mass media as their main source of information, whereas vaccinated patients relied on the recommendations made by oncologists or general practitioners.

Indexed as

COVID-19 infectionCOVID-19 vaccinationpatients with cancersocial platformsvaccine hesitancy

Identifiers

PMID36479255
PMCPMC9716118
OpenAlexW4308005047

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.